Receptor endocytosis and recycling processes contribute to HER2 heterogeneity and membrane dynamics15, affecting antibody-tumor binding and subsequent efficacy and antibody-dependent cytotoxicity (ADCC)-mediated mechanisms16–25. Here, ERBB2 is linked to neoplasm.